NASDAQ:NBIX
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.'s revenue grew 21.4% in fiscal 2025 to $2.9B while operating margin fell to 21.6%. Free cash flow was $748.7M, 26.2% of revenue, and the diluted share count fell 1.2%.Summary generated from Neurocrine Biosciences Inc.'s SEC filings. Latest annual report filed Feb 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.9B
Revenue growth+21.4%
Revenue, 5-yr CAGR+22.3%
Gross margin98.2%
Operating margin21.6%
Net margin16.7%
ROICn/a
Return on equity16.4%
Debt / equityn/a
Free cash flow$748.7M
FCF margin26.2%
Share count change−1.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,134 | 1,489 | 1,887 | 2,355 | 2,861 |
| Operating income | 103 | 249 | 251 | 571 | 619 |
| Net income | 90 | 155 | 250 | 341 | 479 |
| Free cash flow | 233 | 323 | 362 | 557 | 749 |
Recent filings
- 8-KDirector or officer change
Sep 28, 2026 - 4Insider transaction report
Sep 15, 2026 - 4Insider transaction report
Sep 15, 2026 - 8-K/AAmended current report
Jul 31, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 31, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KDirector or officer change
May 28, 2026 - 8-KEntry into a material agreement
May 18, 2026